About Cytonics
Cytonics is a company based in Jupiter (United States) founded in 2006 by Gaetano Scuderi. Cytonics has raised $3.33 million across 8 funding rounds from investors including HHS and NIH SBIR/STTR. The company has 8 employees as of December 31, 2017. Cytonics offers products and services including APIC™ System, FACT™ Diagnostic, and CYT-108. Cytonics operates in a competitive market with competitors including PierianDx, Treos Bio, Circular Genomics, Ignyta and Crescendo Bioscience, among others.
- Headquarter Jupiter, United States
- Employees 8 as on 31 Dec, 2017
- Founders Gaetano Scuderi
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cytonics Corporation
-
Annual Revenue
$417.5 K (USD)3as on Dec 31, 2023
-
Net Profit
-$2.84 M (USD)-48as on Dec 31, 2023
-
EBITDA
Not available
-
Total Equity Funding
$3.33 M (USD)
in 8 rounds
-
Latest Funding Round
$25 K (USD), Seed
Jun 07, 2019
-
Investors
HHS
& 1 more
-
Employee Count
8
as on Dec 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cytonics
Cytonics offers a comprehensive portfolio of products and services, including APIC™ System, FACT™ Diagnostic, and CYT-108.
Autologous treatment using A2M to reduce osteoarthritis pain and inflammation
Test that detects cartilage damage in joint fluid for patient diagnosis
Recombinant A2M therapy aimed at improving cartilage protection in osteoarthritis
People of Cytonics
Unlock access to complete
Unlock access to complete
Funding Insights of Cytonics
Cytonics has successfully raised a total of $3.33M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $25 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cytonics
Cytonics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Cytonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cytonics
Investment portfolio details for Cytonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cytonics
Detailed financials for Cytonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytonics Comparisons
Peer comparison for Cytonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cytonics
Cytonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PierianDx, Treos Bio, Circular Genomics, Ignyta and Crescendo Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetic tests for individualized disease diagnosis are provided.
|
|
| Locked | Locked | Locked |
Developer of cancer vaccines and companion diagnostics
|
|
| Locked | Locked | Locked |
RNA-based diagnostics and therapeutics for depression are developed and provided.
|
|
| Locked | Locked | Locked |
Personalized medicine is developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
Molecular tests for autoimmune and inflammatory diseases are provided.
|
|
| Locked | Locked | Locked |
Biological drug monitoring and molecular diagnostics are manufactured.
|
Detailed competitors of Cytonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytonics
Complete news archive for Cytonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytonics
Cytonics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Cytonics is headquartered in Jupiter, United States. It is registered at Jupiter, Florida, United States.
Joey Bose is the current CEO of Cytonics.
Cytonics is a funded company, having raised a total of $3.33M across 8 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Cytonics is 8.
Annual revenue of Cytonics is $417.5K as on Dec 31, 2023.
Cytonics was founded in 2006 in Jupiter, United States, within the biotechnology sector. Focus is placed on developing diagnostics and therapeutics for osteoarthritis. The flagship product, the Fibronectin-Aggrecan Complex Test (FACT), is utilized to detect cartilage damage from patients joint fluid samples. Operations center on advancing treatments and early detection methods for joint-related conditions.
Cytonics's top competitors include Circular Genomics, PierianDx and Ignyta.
Cytonics offers APIC™ System, FACT™ Diagnostic, and CYT-108.
Cytonics has 2 investors. Key investors include HHS, and NIH SBIR/STTR.